A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA)

Overview

The investigators plan to perform multi-omics technologies, including genomic, transcriptomic, epigenomic and proteomic methods, in patients with metastatic prostate cancer, aiming at uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets.

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: November 1, 2022

Detailed Description

Prostate cancer is the commonest malignancy and the second leading cause of tumor-related death among males worldwide. Though patients with early stage prostate cancer can obtain satisfactory therapeutic efficacy from radical prostatectomy or radiotherapy, the prognosis of men with metastatic prostate cancer (mPCa), especially metastatic castration-resistant prostate cancer (mCRPC), is still poor. Recent years have witnessed the rapid development of the high-throughput technologies, including genomic, transcriptomic, epigenomic and proteomic methods. These techniques are promising in uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets. In the current prospective study, the investigators plan to perform multi-omics technologies in patients with mPCa, aiming at uncovering the mechanism of the tumor progression, identifying distinct tumor subtypes and finding new treatment targets.

Clinical Trial Outcome Measures

Primary Measures

  • Genetic profiling results
    • Time Frame: From baseline (initial diagnosis of PCa), until study completion (48 months)
    • Mutation identified via whole-genome sequencing will be recored.
  • Transcriptional profiling results
    • Time Frame: From baseline (initial diagnosis of PCa), until study completion (48 months)
    • Determining the transcriptomic information of metastatic prostate cancer by performing whole transcriptome sequencing
  • Epigenomic profiling results
    • Time Frame: From baseline (initial diagnosis of PCa), until study completion (48 months)
    • Determining the epigenomic status of specific genes by performing DNA-methylation sequencing

Secondary Measures

  • Protein expression results
    • Time Frame: From baseline (initial diagnosis of PCa), until study completion (48 months)
    • Determing the expression status of centain proteins by performing immunohistochemistry in prostate biopsy specimen

Participating in This Clinical Trial

Inclusion Criteria

  • Pathological confirmation of prostate cancer – Age: ≥40 years old – Bone or visceral metastatic disease confirmed by image examination. – Written informed consent Exclusion Criteria:

  • Patients harbouring other types of cancer besides prostate cancer

Gender Eligibility: Male

Only male patient can enter this study

Minimum Age: 40 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • West China Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Hao Zeng, Vice director of the department of urology – West China Hospital
  • Overall Official(s)
    • Hao Zeng, Dr., Principal Investigator, West China Hospital
  • Overall Contact(s)
    • Jinge Zhao, Dr., 86 13679017572, jingezhao@foxmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.